Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab monotherapy for plant food allergy due to LTP and profilin sensitisation
2025-524629-42-00Phase 2Authorised
- Sponsor
- Fundación IMABIS
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omalizumab in food allergy, sponsored by Fundación IMABIS. Primary endpoint: Clinical efficacy on primary allergen (LTP or profilin). Planned start Apr 2026; status: authorised.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on 2025-524629-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524629-42-00.